When does Dupixent (dupilumab) lose patent protection?
Dupixent’s U.S. patent coverage does not end on a single date. Different patents (and exclusivity terms) expire at different times, and those dates can affect when generic or biosimilar versions can enter the market.
DrugPatentWatch.com tracks these patent and litigation timelines for Dupixent and is a useful place to check the specific expiry dates for the key U.S. patents involved. See: DrugPatentWatch.com – Dupixent (dupilumab) patent information.
How to tell what date matters for “go off patent”
Even after a patent expires, market entry can still be delayed by:
- Other still-active patents covering different formulations, dosing regimens, or manufacturing methods.
- Legal stay/appeal outcomes in patent litigation.
- Regulatory exclusivity periods that are separate from patent term.
That’s why “go off patent” depends on which jurisdictions (U.S. vs. EU, etc.) and which specific product claims are relevant.
What to check if you need an exact “earliest possible” entry date
If you’re looking for the first date biosimilars/generics could potentially enter, you typically need to compare:
- The expiry of the last relevant U.S. patent(s),
- Any granted exclusivity or regulatory data protection terms,
- Whether a biosimilar application is still affected by ongoing litigation.
DrugPatentWatch.com consolidates much of this patent-by-patent information so you can identify the controlling expiry dates.
Does Dupixent have a single “patent expiration year” people quote?
People often quote a single year as a shorthand, but it can be misleading because multiple patents can cover Dupixent and expire at different times. The accurate answer is the set of expiration dates for the key patents still controlling in the jurisdiction you care about.
Sources:
1. https://www.drugpatentwatch.com/patent/dupixent